Advertisement

Topics

vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon

08:30 EDT 3 Aug 2017 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using azeliragon, the Company’s oral antagonist of the Receptor for...

Other Sources for this Article

Investors
vTv Therapeutics Inc.
Michael Gibralter, 646-378-2938
IR@vtvtherapeutics.com
or
Media
Pure Communications Inc.
Katie Engleman, 910-509-3977
Katie@purecommunications.com

NEXT ARTICLE

More From BioPortfolio on "vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon"

Quick Search
Advertisement
 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Searches Linking to this Story